新诺威筹划发行H股股票并在香港联交所上市

Core Viewpoint - The company, Sinopharm, is advancing its global strategy by planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international competitiveness and support the development of its pharmaceutical business [3]. Group 1 - The company is currently in discussions with relevant intermediaries regarding the issuance of H-shares and the listing process [1]. - The board of directors and the supervisory board have approved the proposal to seek shareholder authorization for the application of the initial public offering of overseas listed shares (H-shares) [3]. - The specific details regarding the H-share issuance and listing have not yet been finalized [1].